Floatz logo

Adenovirus-P53 Transduced Dendritic Cell Vaccine

Cancer Of Unknown Primary Site

H. Lee Moffitt Cancer Center and Research InstitutevaccinePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Cancer Of Unknown Primary Site cohort.

Asset / SponsorPhaseRating
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
ETOPOSIDE
University of California, Davis
Phase 2/3BBB
DEXAMETHASONE
Alliance for Clinical Trials in Oncology
Phase 3BBB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Adenovirus-P53 Transduced Dendritic Cell Vaccine is also rated in:

male breast carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →